On October 18, 2024, a Business Insider segment featured insights from AFAR Board Members Nir Barzilai, MD, and Alex Colville, PhD, as well as AFAR Grantee Matt Kaeberlein, PhD, on the future of therapeutics to extend healthspan and treat or delay age-related diseases.
Dr. Barzilai highlighted the need for research studies focused on targeting the biology of aging to extend healthspan, emphasizing the significance of the TAME (Targeting Aging with Metformin) trial, which aims to provide proof of concept that the biology of aging can be targeted through therapeutics.
Dr. Colville noted that the future of aging therapeutics may come from non-traditional solutions with increasing interest from scientists and investors alike.
Dr. Kaeberlein shared insights from the Dog Aging Project, which he co-founded with AFAR grantees Daniel Promislow, DPhil, which is helping to advance knowledge of human aging by studying canine longevity and healthspan.
Dr. Barzilai is a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar and 1994 AFAR Research Grant recipient, as well as the Co-Investigator of the AFAR SuperAgers Family Study, an AFAR Board Member, and author of Age Later: Health Span, Life Span and the New Science of Longevity.
Dr. Colville is General Partner and co-founder of age1, an advisor to the Amaranth Foundation and AFAR’s TIME Initiative.
Dr. Kaeberlein is a 2006 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and a 2007 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient. He is also the 2011 recipient of AFAR’s Vincent Cristofalo Rising Star Award in Aging Research.
Watch “How Longevity Drugs for Dogs Could Lead to Healthier Human Lives” here.
